Top 15 Specialty & Generic Drug Manufacturer Stocks
Marvin's rules ranked 15 specialty and generic drug makers by Overall score within their industry. ANI Pharmaceuticals, Collegium and Zoetis score highest. Margins, growth and debt differ widely across the group.
Specialty and generic drug manufacturers make branded medicines for narrower patient groups, lower-cost versions of established drugs, or animal-health products. This list covers 15 such companies, ordered by Marvin's Overall score, with the highest first.
The companies in this group look quite different from one another. Some have strong profit margins and low debt. Others are growing quickly but are not yet profitable, or carry heavy debt. Each blurb below points out strengths and one caution so you can see both sides.
Marvin's scores compare a company only with others in the same industry, so a high score does not mean the business is strong in absolute terms. Some figures are missing for certain companies, and we note this where it matters.
The list
How Marvin ranked these stocks
Marvin included companies above a minimum size and ranked them by Overall score, from highest to lowest. The scores run from 0 to 100 and are relative to each company's own industry, here Drug Manufacturers - Specialty & Generic. A score therefore shows how a company compares with its industry peers today. It is not a prediction and not a recommendation.
Companies above about $300 million in size, ranked by Marvin scores (0-100, relative to each company's own industry). The Drug Manufacturers - Specialty & Generic industry, highest Overall score first.
The stocks, one by one
ANI Pharmaceuticals, Inc. ANIP
ANI Pharmaceuticals leads the list with an overall score of 96. Revenue grew 43.8% last fiscal year, and an operating margin of 15.4% and free cash flow margin of 17.7% suggest solid profitability. Caution: gross margin data is missing, and debt-to-equity of 0.50 is worth noting.
Collegium Pharmaceutical, Inc. COLL
Collegium scores 92 overall. Its free cash flow margin of 40.6% is very strong, revenue growth of 23.6% is healthy, and operating margin is 19.5%. Caution: debt-to-equity is not available, so its debt load cannot be judged from this data.
Zoetis Inc. ZTS
Zoetis has a quality score of 87 and a gross margin of 71.7%, showing strong profitability on what it sells. Return on equity is 83.8%. Caution: revenue growth was only 2.3%, debt-to-equity of 2.93 is fairly high, and operating margin is not available.
Lantheus Holdings, Inc. LNTH
Lantheus has a quality score of 93, backed by a free cash flow margin of 24.9%, return on equity of 21.0% and low debt-to-equity of 0.48. Caution: revenue growth was nearly flat at 0.5% last fiscal year.
Ironwood Pharmaceuticals, Inc. IRWD
Ironwood scores 87 overall, helped by a very high operating margin of 60.1%, meaning it keeps much of each sales dollar as operating profit. Caution: revenue shrank, with growth of -15.7%, and cash flow, debt and return figures are not available.
Phibro Animal Health Corporation PAHC
Phibro Animal Health grew revenue 17.1% and earned a return on equity of 25.9%, with an operating margin of 12.8%. Caution: free cash flow margin is only 0.6%, so little cash was left over, and debt data is missing.
Indivior Pharmaceuticals Inc INDV
Indivior has a high gross margin of 82.0% and an operating margin of 31.6%, with modest revenue growth of 4.3%. Caution: free cash flow margin was negative at -8.3%, meaning more cash went out than came in, and debt and return figures are missing.
Amphastar Pharmaceuticals, Inc. AMPH
Amphastar shows steady but unspectacular numbers: an operating margin of 15.7%, free cash flow margin of 20.9% and debt-to-equity of 0.89. Caution: revenue slipped, with growth of -1.7%, and return on equity is a modest 10.2%.
Harrow Health, Inc. HROW
Harrow grew revenue 36.4% and has a gross margin of 73.3%. Caution: it is not yet profitable on an operating basis, with an operating margin of -1.0%, and return on equity of -244.9% is deeply negative. Debt data is missing.
Eton Pharmaceuticals, Inc. ETON
Eton's revenue growth of 104.9% is the fastest on this list, alongside an operating margin of 15.4% and return on equity of 27.2%. Debt-to-equity is 0.63. Caution: very fast growth can come from a small starting base.
Amneal Pharmaceuticals, Inc. AMRX
Amneal grew revenue 8.0% and has an operating margin of 14.6%. Caution: debt-to-equity is very high at 77.83, and the huge return on equity of 476.5% can partly reflect heavy borrowing. Free cash flow margin is only 4.1%.
Viatris Inc. VTRS
Viatris has a free cash flow margin of 13.3% and a gross margin of 34.8%, with debt-to-equity of 0.96. Caution: revenue fell, with growth of -3.0%, and operating margin is negative at -0.6%.
Supernus Pharmaceuticals, Inc. SUPN
Supernus has a high gross margin of 88.1% and revenue growth of 8.6%. Caution: operating margin is negative at -15.7%, return on equity is -10.7%, and free cash flow margin is a thin 2.3%. Debt data is missing.
Elanco Animal Health Incorporated ELAN
Elanco has a gross margin of 55.4%, revenue growth of 6.2% and debt-to-equity of 0.59. Caution: free cash flow margin is only 7.5%, return on equity is negative at -3.0%, and operating margin is not available.
Trulieve Cannabis Corp. TRLV
Trulieve Cannabis has a gross margin of 59.5% and debt-to-equity of 0.47. Caution: operating margin is negative at -24.3%, return on equity is -62.2%, and revenue growth was flat to slightly down at -0.4%.
Common questions
What do Marvin's Overall, Quality and Opportunity scores mean?
They are scores from 0 to 100 that compare a company with others in the same industry. Quality reflects the strength of the business, such as profitability and financial health. Opportunity is a separate score, and Overall combines Marvin's measures into one number. None of them predicts future results.
Why are some figures missing for certain companies?
A figure may be unavailable when the underlying financial data is incomplete or a ratio cannot be calculated in a meaningful way. Where a figure is missing, the blurb says so. A missing figure is not the same as a weak one.
Does a higher score mean a stock is a better investment?
No. A higher score only means the company compares better with its industry peers on Marvin's measures today. It does not say whether the stock will rise or fall, and it is not advice. Look at the individual figures and your own situation too.
Keep reading
- Top 15 Healthcare Stocks by Marvin Opportunity Score
- Top 15 Healthcare Companies With the Strongest Businesses
- Top 15 Healthcare Stocks Right Now, Ranked by Marvin Scores
- Top 20 Growth Stocks Right Now
Free account. Build your own AI-made watchlists, follow Marvin's scores and share lists.
Create a free account
Marvin's scores (0-100) compare each company with others in its industry today. Growth and margin figures come from SEC filings. This is general information, not personal investment advice or a recommendation to buy or sell anything. Do your own research.